Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02067975 · ClinicalTrials.gov registry record · Phase 2
Tryptophan MRI in People With Schizophrenia and Healthy Controls
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT02067975 is a Phase 2 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 93 participants.
The verdict
NCT02067975, a Phase 2 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
Kynurenic acid (KYNA) is a naturally occurring chemical in the brain. Studies with rodents indicate that levels of KYNA can impact levels of the neurotransmitters glutamate and dopamine. One way to reliably increase KYNA levels is by ingesting the amino acid tryptophan. Tryptophan is a normal part of the human diet. Tryptophan gets metabolized/changed to other chemicals in the body- including KYNA. By giving people 6 grams of tryptophan, the investigators will be able to increase the KYNA level in a controlled way. The investigators will then be able to study the effects of KYNA on neurotransmitters by using cognitive tests and magnetic resonance imaging techniques (measuring brain activity and brain chemistry using the MRI magnet). They will test people using tryptophan and also using a placebo to look for differences. The investigators will test healthy controls and people with schizophrenia to look for differences.
Interventions
- DRUG Placebo
- DRUG Tryptophan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2014-08-14 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02067975
The ClinicalTrials.gov registry entry for NCT02067975 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02067975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02067975 about?
NCT02067975 is a clinical study titled "Tryptophan MRI in People With Schizophrenia and Healthy Controls". Kynurenic acid (KYNA) is a naturally occurring chemical in the brain. Studies with rodents indicate that levels of KYNA can impact levels of the neurotransmitters glutamate and dopamine. One way to reliably increase KYNA levels is by ingesting the amino acid tryptophan. Tryptophan is a normal part o...
What is the current status of trial NCT02067975?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2014-08-14. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT02067975?
The interventions under investigation include: Placebo (DRUG), Tryptophan (DRUG).
Who is sponsoring clinical trial NCT02067975?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.